| % of the pop. eligible* for trial | % of the eligible pop. that would be excluded** | % of the pop. to which the trial is generalizable |
---|---|---|---|
VA-NHBLI [36] | 9.7 | 14.1 | 8.3 |
HDPF [37] | 28.8 | 0 | 28.8 |
Oslo [45] | 3.3 | 10.6 | 2.9 |
Australia [43] | 18.1 | 5.7 | 17.1 |
MRC [40] | 21.0 | 0 | 21.0 |
VA I [34] | 0.4 | 0 | 0.4 |
VA II [35] | 18.9 | 0 | 18.9 |
PHS [44] | 18.5 | 9 | 16.9 |
HSCSG [33] | 1.2 | 1.1 | 1.2 |
Barraclough [32] | 11.0 | 0 | 11.0 |
Carter [38] | 2.6 | 25 | 1.8 |
EWPHE [39] | 37.4 | 22.3 | 32.8 |
Coope [42] | 14.2 | 22.1 | 11.1 |
MRC – O [29] | 14.8 | 9.7 | 13.2 |
SHEP [41] | 22.0 | 26.5 | 16.2 |
STOP [30] | 2.1 | 3.2 | 2.1 |